🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis (HITs)

RecruitingPhase 4Ages any - anyAllSecond Affiliated Hospital, Zhejiang University, …
NCT04624295 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Previous study showed that the proportions of hemorrhagic Infarction after intravenous thrombolysis were 24.2% and 32.5% in the control group and the alteplase group, and most of them were asymptomatic. Hemorrhagic Infarction was a part of the natural progression after acute ischemic stroke. Previous study have shown no significant relationship between hemorrhagic Infarction and poor outcome in acute ischemic stroke (AIS) patients. In this study, a randomized controlled trial will be conducted to explore the efficacy and safety of early antiplatelet therapy after hemorrhagic infarction in acute ischemic stroke treated with intravenous thrombolysis.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Acute ischemic patients receiving intravenous thrombolysis within 24 hours upon stroke onset 2. Be confirmed as Hemorrhagic Infarction at 24 to 36 hours after intravenous thrombolysis by computerized tomography 3. The patient or family member signed an informed consent Exclusion Criteria: 1. Early use of anticoagulant drugs within 1 week after intravenous thrombolysis; 2. Tirofiban was used after receiving endovascular treatment; 3. Intraoperative stent placement after receiving endovascular treatment; 4. Subarachnoid hemorrhage or ventricular hemorrhage; 5. There are contraindications for aspirin use;
💊

What it tests

  • Early aspirin Therapy
  • Non-Early aspirin Therapy
📍

Where

1 site
the second affiliated hospital of Zhejiang University
Hangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy